29:I[164923,["/_next/static/immutable/chunks/0x-9rc1bm-510.js","/_next/static/immutable/chunks/0u73ovrok9bmr.js","/_next/static/immutable/chunks/3t9ifrnugpnlb.js","/_next/static/immutable/chunks/3gdp0tzp2t65u.js","/_next/static/immutable/chunks/0qexc5596g7lf.js","/_next/static/immutable/chunks/3nkl8euu6dycn.js","/_next/static/immutable/chunks/28p3k9kvs3dfa.js","/_next/static/immutable/chunks/04j_o97cgxn2x.js","/_next/static/immutable/chunks/18bybpoq919w1.js"],"ClinicalTrialDetail"] 28:T815,{"@context":"https://schema.org","@type":"MedicalWebPage","name":"Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)","description":"The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in Sickle Cell Disease (SCD) patients diagnosed with Pulmonary Hypertension. It consists of 3 phases: screening, treatment and follow-up. During the screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the baseline visit the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study some of the patients will be asked to repeat the right heart catheterization. All patients will repeat an exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.","url":"https://clareohealth.com/clinical-trials/NCT00313196","mainEntity":{"@id":"https://clareohealth.com/clinical-trials/NCT00313196"},"specialty":{"@type":"MedicalSpecialty","name":"Clinical Research"},"audience":{"@type":"PeopleAudience","audienceType":"Patients and Caregivers"},"lastReviewed":"2025-02-04","medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"reviewedBy":{"@type":"Organization","name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov"}}25:["$","script","2",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$28"}}] 2a:T56c,The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in Sickle Cell Disease (SCD) patients diagnosed with Pulmonary Hypertension. It consists of 3 phases: screening, treatment and follow-up. During the screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the baseline visit the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study some of the patients will be asked to repeat the right heart catheterization. All patients will repeat an exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.2b:Te56,Inclusion Criteria: Screening Criteria: 1. Males or females \> or = 12 years of age with a documented history of SCD 2. Patients with symptomatic PH associated with shortness of breath 3. Patients with tricuspid regurgitation jet (TRJ) velocity of \> 2.9 m/sec based on echo/Doppler conducted within 6 months prior to randomization and not during SCD crisis 4. Signed written informed consent is obtained from the patient or patient's parent/ legal representative prior to initiation of any study related procedure Inclusion Criteria: 1. Patients with hemoglobin (Hb) SS or Hb S/β0 genotype and with Hb A \< or = 10% 2. Six-minute walk test (6MWT) distance \> or = 150 m and \< or = 450 m 3. Pulmonary hypertension confirmed by right heart catheterization (RHC) performed at the study site within 3 months of the randomization visit and defined as: * Mean pulmonary arterial pressure (mPAP) \> or - 25 mmHg * Pulmonary capillary wedge pressure (PCWP) measured by right heart catheterization or left ventricular end diastolic pressure (LVEDP) measured by left heart catheterization, if PCWP measurement is not reliable. Two subsets of patients will be considered for this study: * PCWP \< or = 15 mm Hg, if PVR at rest \< 160 dyn.sec/cm5 * PCWP of 16-25 mm Hg with any PVR value 4. Women of childbearing potential must have a negative result on their serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination Exclusion Criteria: 1. Left ventricular ejection fraction \< 40% (echo/Doppler) 2. Systolic blood pressure (SBP) \< 85 mmHg 3. Uncontrolled hypertension with SBP \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg 4. Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC) \< 0.5 5. Total lung capacity (TLC) \< 50% of normal predicted value 6. Significant cardiac disease: ischemic, valvular, constrictive 7. Hemoglobin concentration \< 6.0 g/dL at the time of randomization 8. Acute liver disease 9. cirrhosis or portal hypertension 10. ALT \> or = 2 times upper limit of normal (ULN) and/or albumin \< 2.8 g/dL 11. Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (in particular with 6MWT), e.g., angina pectoris, intermittent claudication, symptomatic hip osteonecrosis 12. Vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within 2 weeks of randomization or more than 12 VOC and/or ACS within the last 12 months 13. Blood transfusion within 4 weeks prior to randomization 14. Illness with a life expectancy shorter than 6 months 15. HIV with opportunistic infection 16. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements 17. Pregnant or lactating women 18. Recently started (\< 8 weeks prior to randomization) or planned, exercise-based cardio-pulmonary rehabilitation program 19. Bone marrow transplantation 20. Treatment or planned treatment with another investigational drug within 3 months prior to randomization 21. Treatment for pulmonary hypertension with an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, prostanoids (excluding acute administration during a catheterization procedure to test vascular reactivity) within 3 months prior to randomization or with L-arginine within 1 week prior to randomization 22. Treatment with calcineurin-inhibitors (e.g., cyclosporine A and tacrolimus), sirolimus, fluconazole, amiodarone, miconazole and glibenclamide (glyburide) within 1 week prior to randomization 23. Known hypersensitivity to bosentan or any of its excipients26:["$","$L29",null,{"trial":{"nctId":"NCT00313196","briefTitle":"Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)","officialTitle":"Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease","briefSummary":"$2a","detailedDescription":null,"overallStatus":"TERMINATED","phase":"PHASE3","studyType":"INTERVENTIONAL","conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"bosentan","description":"Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg"}],"keywords":["Pulmonary Hypertension","Sickle Cell Disease","Sickle cell anemia","bosentan","ASSET","ASSET-2"],"locations":null,"eligibilityCriteria":"$2b","minAge":12,"maxAge":null,"sex":"ALL","healthyVolunteers":false,"leadSponsor":"Actelion","collaborators":null,"contacts":null,"startDate":"$D2006-04-01T00:00:00.000Z","completionDate":"$D2007-08-01T00:00:00.000Z","primaryCompletionDate":"$D2007-08-01T00:00:00.000Z","firstPostDate":"$D2006-04-12T00:00:00.000Z","lastUpdatePostDate":"$D2025-02-04T00:00:00.000Z","enrollmentCount":12,"enrollmentType":"ACTUAL","aiSummary":"$undefined","aiSummaryGeneratedAt":null,"id":"$undefined","createdAt":"$undefined","updatedAt":"$undefined"}}]

What this study is about